OncLive presents Priyanka Sharma, MD, and Lajos Pusztai, MD, PhD
Node-negative cancer
Whether patients have node-negative or node-positive breast cancer, the Breast Recurrence Score test is both prognostic and predictive – providing both important prognostic information about the estimated risk of distant recurrence and the likelihood of adjuvant chemotherapy benefit.
1-6
Learn more about the study results:
Prognostic Clinical Trial Results:
Predictive Clinical Trial Results:
Predictive Clinical Trial Results:
Node-Negative Prognostic Clinical Trial Results
The Recurrence Score result is directly associated with the rate of distant recurrence.1, 4
NSABP B-14 Study
10-year rate of distant recurrence was significantly lower for patients with low Recurrence Score results compared to high results
Prospective analysis of archived tissue from 668 stage I or II patients with estrogen receptor (ER)-positive, node-negative, invasive breast cancer treated with tamoxifen. Twenty-nine percent of patients were < 50 years of age, and 62% had tumors that were ≤ 2.0 cm in size. The majority of patients (51%) in this study had low Recurrence Score results.
1
Node-Negative Predictive Clinical Trial Results
Only the Oncotype DX Breast Recurrence Score test predicts the likelihood of chemotherapy benefit for node-negative patients.2
NSABP B-20 Study: Low Recurrence Score result predicted little to no benefit from chemotherapy
NSABP B-20 Study: High Recurrence Score result predicted large benefit from chemotherapy
Prospective analysis of archived tissue from 651 patients with ER-positive, node-negative, invasive breast cancer treated with tamoxifen or tamoxifen plus CMF/MF. Approximately 45% of the patients were < 50 years of age, two-thirds of tumors were ≤ 2.0 cm in size, and 16% of tumors were progesterone receptor-negative.
2
Node-Negative Predictive Clinical Trial Results